In human tumor samples, researchers found that the content of RIPK3 was reduced, such as acute myeloid leukemia [32], chronic lymphocytic leukemia [33], as well as common colorectal cancer [34] and breast cancer in clinical practice. Here, RIPK3 is linked to B-cell chronic lymphocytic leukemia.